Lynparza secures third EU nod; Protein degradation biotech grabs $16M launch round from Chinese VCs; Wave shares tumble on trial delay
→ Lynparza, the first PARP inhibitor from AstraZeneca $AZN to win US approval in 2014, has secured its third EU approval. The drug won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
